Anagenics Ltd (an1) Logo

Anagenics Ltd (AN1)

___:___ · Consumer Defensive

AN1 Chart


AN1's Principal Activity is the advangen Limited (Advangen):- During FY2019 Advangen continued with the development and sale of over-the-counter (OTC) and cosmetic products for hair loss and anti-aging hair care using proprietary FGF5 inhibitor technology

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -54.73%


Market Capitalisation
ASX Rank 2,062 of 2,397
Sector Rank 84 of 95

Key Fundamentals

Shares Issued
Sector Consumer Defensive
Similar Companies CDY / HCT / YOW
EPS -$0.024
DPS $0.00
NTA per share $0.05

Broker Consensus

AN1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Cellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company holds global intellectual properties relating to novel targets midkine and FGF5.

Incorporation Details

Incorporated Medical Therapies Limited was incorporated on 8 October 2004 in New South Wales. Code changed to Cellmid Limited (CDY) on 19/11/2009.

Corporate Details

Head Office Sydney NSW 2000
Registry Automic Group
Auditor Pitcher Partners
Date Listed 9 Dec 2005

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Phillip Christopher Non-Executive Director Nov 2021

Mr Phillip Christopher

Non-Executive Director

Mr Christopher is an investment professional with over 12 years of experience across private equity, mergers and acquisitions and capital markets. He has led a range of strategic investments throughout his career and provided board level support, corporate and commercial advice to investee companies. He is Investment Director of HGL Limited where he has been responsible for advising and guiding private investments including BLC Cosmetics prior to its acquisition by Cellmid. He also spent 6 years at Alceon Group where he was a director in the private equity team which made investments in e-commerce and proprietary brand-based businesses. Prior to that he was a member of the investment banking division of Goldman Sachs. He is a director of Pegasus Healthcare and was previously an alternate director of Marlin Brands.

Mr Lee Tamplin Company Secretary Sep 2018
Mr Dennis Eck Non-Executive Director Mar 2018

Mr Dennis Eck

Non-Executive Director

Mr Eck has 40 years senior management experience in the retail sector, strategic and operational functions. Mr Eck, a professional investor, has retail experience in fashion, groceries, cosmetics, and hair salons. As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses delivering outstanding shareholder returns.

Dr Martin George Cross Non-Executive Director Oct 2017

Dr Martin George Cross

Non-Executive Director

Dr Cross has Over 35 years of experience working in the pharmaceutical and biotech industries primarily in all aspects of marketing, selling and business management. This included global roles at international headquarters of AstraZeneca and Novartis. Former Country President for Novartis Australia/ NZ, Managing Director for Alphapharm (Mylan) Australia/NZ with extensive retail experience in pharmacies and Chairman of the Generics Industry Association and Medicines Australia.

Mr Bruce Robin Gordon Non-Executive Director,Non-Executive Chairman Jul 2015

Mr Bruce Robin Gordon

Non-Executive Director,Non-Executive Chairman

Mr Gordon is an experienced finance professional with a career spanning more than 35 years advising and providing financial services to private and publicly listed companies as well as subsidiaries of large multinationals.

Ms Maria Halasz Chief Executive Officer,Managing Director Nov 2007

Ms Maria Halasz

Chief Executive Officer,Managing Director

Ms Halasz has 28 years of experience in life sciences working in executive positions in private and public companies, managing investment funds and holding senior positions in corporate finance in life sciences. Maria has been CEO and Managing Director of Cellmid since April 2007.

Director Transactions

AN1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/01/22 Dennis Eck Issued 803,858 $0.062 $50,000 Director remuneration
01/04/21 Maria Halasz Issued 713,819 $0.078 $55,677 Rights issue
01/04/21 Martin Cross Issued 65,000 $0.078 $5,070 Rights issue
01/04/21 Martin Cross Issued 130,000 $0.075 $9,750 Rights issue
01/04/21 Dennis Eck Issued 2,592,518 $0.078 $202,216 Rights issue

Director Interests

The current holdings of AN1 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Dennis Eck 07/01/2022 18,951,483 N/A 2,592,518 N/A
Phillip Christopher 05/11/2021 0 N/A N/A N/A
Maria Halasz 22/09/2021 588,000 4,412,000 3,713,819 N/A
Martin Cross 30/06/2021 N/A 455,000 65,000 N/A
Bruce Gordon 30/06/2021 N/A 364,000 52,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 16, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Mr Dennis Keith Eck 18,147,625 9.68%
P & M Maguire Super Pty Ltd (P & M Maguire S/F A/C) 8,800,000 4.70%
Moore Family Nominee Pty Ltd (Moore Family Super Fund A/C) 8,425,020 4.50%
Maria Halasz 4,637,639 2.47%
Iq Global Asset Partners Pty Ltd (Iq S/F A/C) 4,462,376 2.38%
Ubs Nominees Pty Ltd 3,663,378 1.95%
Mr Antony Stephen Iles 3,000,000 1.60%
Ms Janet Heather Cameron 2,958,618 1.58%
Ltl Capital Pty Ltd 2,583,333 1.38%
Jasgo Nominees Pty Ltd (Jasgo Family A/C) 2,331,578 1.24%
Seistend (Super) Pty Ltd (Dw King Super Fund A/C) 2,121,000 1.13%
Scintilla Strategic Investments Limited 2,100,000 1.12%
Mr Peter Howells 2,035,000 1.09%
Mr Gregory Glenn Worth (Worth S/F A/C) 2,000,000 1.07%
Citicorp Nominees Pty Limited 1,938,564 1.03%
Evaneu (Nominees) Pty Ltd & Ricneu (Nominees) Pty Ltd (The Evan Ricky Neumann A/C) 1,905,618 1.02%
Mrs Rebecca Shalala 1,859,029 0.99%
Mr Gerald William Simms 1,750,000 0.93%
Mrs Margaret Ann Ryan & Mr Micheal Rodney Ryan 1,550,000 0.83%
Mr Jon David Wood 1,500,000 0.80%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 81 760 369 800 270 2,280

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Dennis Keith Eck 16/08/2021 18,147,625 9.68
HGL Limited 02/11/2021 35,157,956 15.97

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
02-11-21 HGL Limited 35,157,956 -- 15.97

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
AN1 Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.